Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

CVD Still the Leading Cause of Death and Disease Globally

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

VANISH2 Bolsters Data Backing VT Ablation in Ischemic Cardiomyopathy

News Conference News HRS 2025

VANISH2 Bolsters Data Backing VT Ablation in Ischemic Cardiomyopathy

April 29, 2025

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

Positive Results With Carillon Mitral Device Seen in Real-world Registries

News Conference News THT 2025

Positive Results With Carillon Mitral Device Seen in Real-world Registries

February 21, 2025

ACC Offers ‘Practical Document’ for Myocarditis Diagnosis and Care

News Daily News

ACC Offers ‘Practical Document’ for Myocarditis Diagnosis and Care

December 11, 2024

Acute HF Patients Live Longer When Seen by Specialists

News Daily News

Acute HF Patients Live Longer When Seen by Specialists

Michael O'Riordan

August 09, 2024

The Hole Story: Interatrial Shunt Companies Are—Mostly—Pushing Ahead

News Daily News

The Hole Story: Interatrial Shunt Companies Are—Mostly—Pushing Ahead

Michael O'Riordan

June 20, 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

News Conference News ESC Heart Failure 2024

Better Natriuresis With IV Furosemide and Metolazone in Chronic HF Patients

Michael O'Riordan

May 13, 2024

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

News Daily News

SGLT2 Inhibitor Added to GDMT in Functional MR May Obviate Need for TEER

Michael O'Riordan

May 07, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

Reduced EF Evident in Some Elite Endurance Athletes

News Daily News

Reduced EF Evident in Some Elite Endurance Athletes

Michael O'Riordan

December 21, 2023

Real-world MitraClip Impact in Secondary MR: Reassuring for Some, Not All

News Daily News

Real-world MitraClip Impact in Secondary MR: Reassuring for Some, Not All

Michael O'Riordan

September 18, 2023

ESC Cardiomyopathy Guidelines Span Range of Phenotypes

News Conference News ESC 2023

ESC Cardiomyopathy Guidelines Span Range of Phenotypes

Yael L. Maxwell

August 31, 2023

PCI Doesn’t Cut Arrhythmias in Severe LV Dysfunction: REVIVED-BCIS2 Analysis

News Daily News

PCI Doesn’t Cut Arrhythmias in Severe LV Dysfunction: REVIVED-BCIS2 Analysis

August 14, 2023

For Some, Hopes for a Heart Grow Dim as LVAD-Only Centers Spread

News Daily News

For Some, Hopes for a Heart Grow Dim as LVAD-Only Centers Spread

Michael O'Riordan

January 30, 2023

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

News Daily News

FDA Advisors Recommend Against Approval of Omecamtiv Mecarbil

Michael O'Riordan

December 14, 2022

GDMT With ARNI Lessens MR, Perhaps Obviating Need for Interventions

News Conference News HFSA 2022

GDMT With ARNI Linked to Less MR, May Obviate Need for Interventions

Michael O'Riordan

October 04, 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

News Conference News ESC 2022

PCI No Better Than GDMT in Ischemic Cardiomyopathy: REVIVED-BCIS2

Michael O'Riordan

August 27, 2022

New HF Guidelines Stress Four Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

April 01, 2022

Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’

News Daily News

Prognosis of Myocarditis Following COVID-19 Vaccination ‘Favorable’

Michael O'Riordan

March 28, 2022

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.